Adial Pharmaceuticals, Inc. (ADIL) on Monday said it has submitted its AD04 application for consideration under the U.S. Food and Drug Administration Commissioner's National Priority Voucher Pilot Program (CNPV).
The program allows companies to receive an expedited review of a drug application, including closer interaction with the FDA and a rolling review process.
Cary Claiborne, President and Chief Executive Officer of Adial, commented, "As we continue to advance the AD04 program and actively plan for the next phase of our clinical development efforts, we believe the Commissioners National Priority Voucher Pilot Program is an excellent strategic fit for AD04 and aligns well with our ongoing collaboration with the FDA."
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.